Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...
More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...
Several months into a multiyear quest to “rigorously prioritize” its pipeline, Takeda is cutting a handful of ...
Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...
Define Ventures identifies about 20 health tech startups, including Innovaccer, Hinge Health & Devoted Health that are poised ...
Blackstone is raising a new life sciences fund, targeting at least $5B after initial $1.6B closing. Blackstone Life Sciences ...
Takeda CEO Christophe Weber will step down next June after more than 10 years leading the Japanese drugmaker. Julie ...
Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...
Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...
Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP-1 drugs while facing potential legal challenges.
Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.
German CDMO Rentschler Biopharma is closing down its cell and gene therapy operations and shutting a facility in the UK, which could affect up to 30 employees.